News

Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

European patents expand coverage for both essential components of FemBloc for fallopian tube occlusion, resulting in non-surgical permanent contraceptionATLANTA, Jan.…

11 months ago

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel…

11 months ago

TOMI Environmental Reports Strong Start to 2025 with January Revenue Growth

FREDERICK, Md., Jan. 30, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in…

11 months ago

Stereotaxis Announces First GenesisX Robotic System Order

ST. LOUIS, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for…

11 months ago

Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering…

11 months ago

Liberation Labs Closes $50.5 Million Convertible Note

Brings total deployable capital raised to date to $125 million and will enable completion of first biomanufacturing plant in Richmond,…

11 months ago

Rentschler Biopharma announces strategic realignment of its global business operations

LAUPHEIM, Germany, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO)…

11 months ago

Reviva to Participate in the 2025 BIO CEO & Investor Conference

CUPERTINO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage…

11 months ago

Evaxion announces pricing of $10.8 million public offering

COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™…

11 months ago

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Boston (January 30, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to…

11 months ago